프레스티지바이오로직스
Financials
Valuation Metrics
프레스티지바이오로직스's Market Cap is ₩987B. At end of 2025 it was ₩2360B. Ranked #1289 of 2,421 in KR market (top 53%), #707 of 1,640 on KOSDAQ (top 43%), #142 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 98.67B KRW | KR#1,289/2,421 Sec#142/231 |
| Revenue | 12.53B KRW | KR#2,254/2,421 Sec#170/231 |
| Net Income | -27.47B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 270.29B KRW | KR#1,101/2,421 Sec#77/231 |
| Net Assets | 135.20B KRW | KR#1,202/2,421 Sec#90/231 |
| Employees | 211 | KR#1,062/2,421 Sec#88/231 |
| Value | ||
| P/B | 0.73x | KR#1,171/2,421 Sec#69/231 |
| P/S | 7.87x | KR#2,236/2,421 Sec#157/231 |
| FCF Yield | -23.85% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -20.32% | KR#2,099/2,421 Sec#164/231 |
| ROA | -10.16% | KR#2,107/2,421 Sec#161/231 |
| Op. Margin | -268.74% | KR#2,345/2,421 Sec#191/231 |
| Revenue Growth | 477.83% | KR#12/2,421 Sec#5/231 |
| Financial Health | ||
| Debt Ratio | 99.91% | KR#1,558/2,421 Sec#179/231 |
| Total Debt | 124.12B KRW | KR#659/2,421 Sec#39/231 |
| FCF | -23.53B KRW | KR#1,933/2,421 Sec#187/231 |
| Cash | 1.58B KRW | KR#2,285/2,421 Sec#215/231 |
| Current Ratio | 0.40x | KR#2,185/2,421 Sec#212/231 |
| Performance | ||
| 1Y Return | -65.04% | KR#2,261/2,421 Sec#214/231 |
| 1M Return | -28.71% | KR#2,351/2,421 Sec#220/231 |
| From 52W High | -67.04% | KR#2,117/2,421 Sec#173/231 |
| 1Y MDD | -66.34% | KR#1,810/2,421 Sec#151/231 |
| Trading | ||
| Volume | 137,004 shares | KR#634/2,421 Sec#54/231 |
| Trading Value | 176.8M KRW | KR#1,319/2,421 Sec#133/231 |
| Foreign Own. | 41.63% | KR#55/2,421 Sec#4/231 |
| Per Share | ||
| EPS | -353 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,739 KRW | KR#2,131/2,421 Sec#177/231 |
Company Info
Prestige Biologics, established in 2015 and listed on KOSDAQ in 2021, specializes as a contract manufacturing organization for biopharmaceuticals. The company conducts CDEMO business, providing customized contract manufacturing services for advanced biopharmaceuticals with a 6,000L production facility at its first plant. Its second campus features the ALITA platform, integrating a Smart Factory platform with diverse production methods to enable versatile product manufacturing. Prestige Biologics is headquartered in Cheongju-si, Chungcheongbuk-do.